Table 1.
Patients’ characteristics at diagnosis.
| Characteristics | |
| Patients, n | 123 |
| M/F, n (%) | 48/75 (39.0/60.9) |
| Median age at diagnosis, years (range) | 80 (75–96) |
| SOKAL score, n (%) | |
| Low | 1 (0.8) |
| Intermediate | 88 (71.5) |
| High | 34 (27.6) |
| ELTS, n (%) | |
| Low | 4 (3.2) |
| Intermediate | 76 (61.7) |
| High | 43 (34.9) |
| Comorbidities at diagnosis, n (%) | 118 (95.9) |
| Median CCI (range) | 1 (0–5) |
| CCI 0, n (%) | 55 (44.7) |
| CCI 1, n (%) | 28 (22.6) |
| CCI ≥ 2, n (%) | 40 (32.5) |
| Median comorbidities per patient (range) | 3.21 (0–9) |
| Cardiovascular disease, n (%) | 101 (82.1) |
| Arterial hypertension | 58 (47.1) |
| Chronic ischemic heart disease | 7 (5.6) |
| Acute myocardial infarction | 10 (8.1) |
| Atrial fibrillation | 13 (10.4) |
| Stroke | 6 (4.8) |
| Transient ischemic attack | 7 (5.6) |
| Chronic obstructive pneumonia disease, n (%) | 13 (10.5) |
| Chronic kidney disease, n (%) | 12 (9.7) |
| eGFR (CKD-EPI) < 30 mL/min | 16 (13.0) |
| eGFR (CKD-EPI) 30–60 mL/min | 38 (30.8) |
| Dyslipidemia, n (%) | 43 (34.9) |
| Diabetes mellitus type 2, n (%) | 13 (10.4) |
| Benign prostatic hyperplasia, n (%) | 20 (16.2) |
| Cancer history, n (%) | 22 (17.8) |
| Breast cancer | 6 (4.8) |
| Colorectal cancer | 3 (2.4) |
| Prostatic cancer | 9 (7.1) |
| Other cancer | 11 (8.9) |
| Patients in treatment for any causes, n (%) | 116 (94.3) |
| Median drugs per patient (range) | 4.57 (0–13) |
| Polypharmacy (>5 drugs), n (%) | 58 (47.1) |
| Smokers, n (%) | 14 (11.3) |
CCI, Charlson Comorbidity Index; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; ELTS, EUTOS Long-Term Survival; eGFR, estimated Glomerular Filtration Rate.